Diosmetin overcomes resistance to cisplatin in ovarian cancer by suppressing the MAPK signaling pathway
{{output}}
Cisplatin (DDP) is a widely used chemotherapeutic agent for ovarian cancer (OC) therapy. However, the adverse effects and frequent resistance to DDP make its therapeutic efficacy suboptimal. Combination treatment with an agent capable of overcoming DDP resista... ...
